Principal Investigator
|
|
Alvaro Aytes, Ph.D.
Group Leader, Department of Molecular Mechanisms and Experimental Therapies in Oncology, IDIBELL Principal Investigator, Program Against Cancer Therapeutic Resistance (ProCURE) IDIBELL and ICO joint initiative Member, Prostate Cancer Functional Unit, Hospital Universitari de Bellvitge I obatained my Ph.D. in Cell Biology and Pathology from Universtiy of Barcelona in 2008 and in 2009 I joined the laboratory of Dr. Abate-Shen as a postdoctoral fellow at Columbia University (New York) working on developing genetically-engineered mouse models and computational approaches to uncover acctionable driver mechanisms in prostate cancer. In 2015 I was recruited as faculty at the joint initiative from IDIBELL and the Catalan Institute of Oncology to launch the Program Against Cancer Therapeutic Resistance. |
Lab members
|
|
Sònia Farran Matas
Ph.D. candidate B.S. MSs Sonia´s Master´s thesis focuses on dissecting the cell cycle independent functions of the master regulators FOXM1 and CENPF, with a particular interest in epigentically controlled oncogen activation. While she continues that line of research she is also focusing on the role PARPi in HDR proficient prostate cancer tumors. |
|
|
Adrian Martínez-Tebar
Ph.D. candidate B.S. MSs Adrian perfomed his Master´s thesis in the Vall d'Hbron Research Institute (VHIR). In our lab he is developing tools and assays for CRISPR/cas9-based genome wide and targeted screenings for synthetic lethal interactions and mecghanisms of resistance to AR targeting agents such as Abiraterone or other novel anti-AR. |
|
|
Former Lab members
|
|
Katia Ruggero
|
|
|
Maialen de la Cuesta Etxeberria
|
|
|
Alba Calvet Pavon
|
